Frontiers Media

Global $46.7B Cancer Biomarkers Market Outlook, 2035: MET Biomarkers Lead the Charge, Driven by Rising Incidence of Lung Cancer and Drug Development - ResearchAndMarkets.com

Retrieved on: 
星期三, 五月 8, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Foundation Medicine, MSI, Lung cancer, Breast cancer, Blood, AI, MDPI, Skin cancer, Agilent Technologies, Prostate cancer, Biomarker, ALK, Kidney cancer, EGFR, OncoDNA, Cancer, Bladder cancer, Tempus, Son, Non-small-cell lung cancer, Frontiers Media, HER2, Colorectal cancer, Turbine, Thyroid cancer, ARUP Laboratories, Roche, Database, Therapy, Merck, NSCLC, Thermo Fisher Scientific, Nature, Publication, Laboratory, Survival, Insurance, BioMed Central, Nature Portfolio, Incidence, Drug development, Liver cancer, Liquid biopsy, MET, NTRK, CK Life Sciences, Endometrial cancer, Actuate, PD-L1, Patient, Gastrointestinal cancer, Physician, Neoplasm, Head, Medical imaging

Based on the type of cancer, the cancer biomarkers market is segmented into Breast Cancer, Prostate Cancer, Colorectum Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia.

Key Points: 
  • Based on the type of cancer, the cancer biomarkers market is segmented into Breast Cancer, Prostate Cancer, Colorectum Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia.
  • Currently, the market is driven by breast cancer biomarkers and lung cancer biomarkers; however, in the coming future, we anticipate cancer biomarker market for leukemia to grow at a significant pace.
  • The market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the companies involved in the cancer biomarkers market.
  • It is worth mentioning that Merck is conducting the maximum number of trials in this industry for various cancer indications, including bladder cancer, breast cancer, colorectal cancer, gastrointestinal cancer, gynecological cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer and skin cancer.

DiagnaMed’s BRAIN AGE® Brain Health AI Platform Accomplishes Clinical Validation Milestone with Peer-Reviewed Paper

Retrieved on: 
星期四, 四月 25, 2024
Frontiers Media, AI, Health, Sport, BRAIN, Machine learning, IRB, Workplace, Doctor of Philosophy, Research, Intelligence, Mental health, Patient, Clinic, Physician, Drexel University, Athlete, EEG, Stockton University, Medical imaging

TORONTO, April 25, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, today announced a clinical validation milestone of the BRAIN AGE® Brain Health AI Platform (“BRAIN AGE®”), a world-first consumer brain health and wellness AI solution that estimates brain age and provides a brain health score, with a first-of-a-kind peer-reviewed paper in Frontiers in Neuroergonomics , titled “Brain-age estimation with a low-cost EEG-headset: effectiveness and implications for large-scale screening and brain optimization”.1

Key Points: 
  • TORONTO, April 25, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, today announced a clinical validation milestone of the BRAIN AGE® Brain Health AI Platform (“BRAIN AGE®”), a world-first consumer brain health and wellness AI solution that estimates brain age and provides a brain health score, with a first-of-a-kind peer-reviewed paper in Frontiers in Neuroergonomics , titled “Brain-age estimation with a low-cost EEG-headset: effectiveness and implications for large-scale screening and brain optimization”.1
    Fabio Chianelli, CEO of DiagnaMed, commented: “The validation of BRAIN AGE® in a peer-reviewed paper is a significant milestone for us that culminates nearly two years of research and now unlocks the potential of BRAIN AGE® for the millions of people seeking to improve their overall brain health.
  • The technology could help to make early, regular screening for degenerative brain diseases more accessible.
  • And because of its low cost, a person can be screened at regular intervals to check for changes over time,” Kounios said.
  • Essentially, BRAIN AGE® can raise the possibility of large-scale detection and treatment of the earliest phases of age-related neurological disorders rather than later.

Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting

Retrieved on: 
星期一, 四月 29, 2024
Vitamins, Supplements, Other Health, Retail, Other Science, Pharmaceutical, Research, Optical, Convenience Store, Medical Devices, Discount, Variety, Science, Clinical Trials, Medical Supplies, General Health, Surgery, Other Retail, Health, Specialty, Hydrogen, Verge, PAF, Frontiers Media, Efficacy, Safety, Trial of the century, Bausch & Lomb, MD, Erythritol, Development, Natural language, Convention (norm), Telecanthus, Research and development, Hosten, Toxicity, Comparison, Wood drying

The posters highlight the results of studies evaluating consumer, pharmaceutical, surgical and vision care products from the company’s broad eye care portfolio, as well as pipeline innovations.

Key Points: 
  • The posters highlight the results of studies evaluating consumer, pharmaceutical, surgical and vision care products from the company’s broad eye care portfolio, as well as pipeline innovations.
  • “A Natural Language Processing Approach to Identify Patients with Uveitic Macular Edema in the IRIS® Registry.” Jin et al.
  • “Clinical Evaluation of a Multi-Ingredient Oral Supplement on Dry Eye Symptoms and Tear Volume.” Barbour et al.
  • “Impact of Pupil Size on Vision Performance of a New Multifocal Daily Disposable Contact Lens.” Reindel et al.

Bellabeat Unveils Next-Gen IVY Health Tracker for Women: A Leap Forward in Advanced Temperature Tracking and Wellness

Retrieved on: 
星期二, 三月 19, 2024
Research, Temperature, Health, Medicine, Frontiers Media, Menstrual cycle, IVY, Heart rate, Ovulation, Journal, Fertility, Pregnancy, Woman, Reproductive biology, Skin temperature, Machine learning, Menstruation, Map, Endocrinology, Birth control

San Francisco, California--(Newsfile Corp. - March 19, 2024) - In its latest endeavor to revolutionize women's health technology, Bellabeat has launched the new IVY+ Health Tracker.

Key Points: 
  • San Francisco, California--(Newsfile Corp. - March 19, 2024) - In its latest endeavor to revolutionize women's health technology, Bellabeat has launched the new IVY+ Health Tracker.
  • It is equipped with a sophisticated temperature tracking feature, marking a significant advancement in menstrual and fertility tracking.
  • In conjunction with the Bellabeat app, the IVY+ Health Tracker transforms biometric data into actionable wellness insights.
  • The combination of the IVY+ Health Tracker and the Bellabeat app creates a comprehensive health monitoring experience that extends beyond traditional tracking methods.

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
星期五, 三月 29, 2024
Patient, PTCL, G&A, IND, Prednisone, Neoplasm, Therapy, SMDC, Medicinal chemistry, Lymphoma, Research, Frontiers Media, RNA polymerase II, Body modification, Primate, RNA, NIH, CPT, Potential, Safety, CDK9, ADC, MCL1, Solubility, Oncogene, RNA polymerase, Venetoclax, Journal, Manuscript, Cancer, Peripheral T-cell lymphoma, AACR, Antibody, MYC, Downregulation and upregulation, DLBCL, Annual general meeting, HER2, European Hematology Association, EHA, Spacecraft, PDX, Bangladesh Technical Education Board, Journal of Medicinal Chemistry, Blood, Pharmaceutical industry

PALO ALTO, Calif., March 29, 2024 (GLOBE NEWSWIRE) --  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Vincerx presented preclinical data at the 2023 AACR Annual Meeting demonstrating significant activity in patient-derived xenograft (PDX) lymphoma mouse models.
  • Vincerx shared preclinical data at the 2023 ASH Annual Meeting showing superior activity and safety compared with commercially available B-cell targeted ADCs.
  • For the fourth quarter and full year 2023, Vincerx reported a net loss of $4.9 million, or $0.23 per share, and a net loss of $40.2 million, or $1.89 per share, respectively.
  • For the fourth quarter and full year 2022, Vincerx reported a net loss of $13.8 million, or $0.65 per share, and a net loss of $63.0 million, or $3.00 per share, respectively.

ImpriMed to Present Innovative Research at 2024 World Veterinary Cancer Congress

Retrieved on: 
星期三, 三月 20, 2024
Pharmaceutical, Data Management, Oncology, Consumer, Technology, Medical Devices, Artificial Intelligence, Health Technology, Clinical Trials, Veterinary, Biotechnology, Health, Pets, B-cell lymphoma, Congress, Flow cytometry, Intelligence, Patient, Survival, RBCL, AI, Medicine, Lymphoma, Trial of the century, WVCC, Frontiers Media

WVCC -- ImpriMed , a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, today announced the company’s participation at the upcoming World Veterinary Cancer Congress (WVCC) 2024 in Tokyo, Japan, from March 21-24, 2024.

Key Points: 
  • WVCC -- ImpriMed , a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, today announced the company’s participation at the upcoming World Veterinary Cancer Congress (WVCC) 2024 in Tokyo, Japan, from March 21-24, 2024.
  • Lim’s presentation will summarize the remarkable results of an ImpriMed study published in Frontiers in Oncology that validate the efficacy of AI-driven drug response predictions in treating canine lymphoma.
  • These results, highlighted by Lim’s presentation, demonstrate AI’s powerful application in producing improved clinical outcomes and revolutionizing veterinary oncology.
  • "We are honored to advocate for AI’s transformative power by sharing our latest findings at the World Veterinary Cancer Congress," said Lim.

Best Life Insurance Plans for Multiple Sclerosis (MS) Patients - Our Top Picks for 2024

Retrieved on: 
星期二, 三月 12, 2024
Survival, ICC, Patient, History, SBLI, Legal & General, Research, Risk, Policy, Lincoln National Corporation, AEGON, Privacy, Hypertension, Disability, Database, Frontiers Media, Journal, Prescription, Neurosurgery, Roger Hawkins (drummer), MD, Insurance, Diagnosis, Psychiatry, Incidence, Prudential Financial, Mortality, Multiple sclerosis, Mutual, Corebridge Financial, Comorbidity, John Hancock Financial, Pharmaceutical industry

Michelle Zieba, Vice President of Sales, described the life insurance application process, "After receiving initial quotes, our MS customers will then be advised by our life insurance experts as to which plan is best.

Key Points: 
  • Michelle Zieba, Vice President of Sales, described the life insurance application process, "After receiving initial quotes, our MS customers will then be advised by our life insurance experts as to which plan is best.
  • A small number of people with Multiple Sclerosis experience very mild symptoms and little to no disability.
  • Zieba offered this advice to those with MS who are shopping for life insurance, "MS patients can do a lot to prepare to buy life insurance.
  • Instant life insurance quotes for those with Multiple Sclerosis of all severities are available at www.lifequotes.com .

Ruavieja brings you another moving Christmas campaign

Retrieved on: 
星期四, 十一月 30, 2023
Frontiers Media, Advertising, Collection, University, University of Louisville, Ageing, Projection, Life, Film industry

MADRID, Nov. 30, 2023 /PRNewswire/ -- Leading Galician liqueur brand Ruavieja has launched "The movie of your life," its Christmas campaign designed by TBWA\Spain, the creative agency led by Juan García-Escudero. The project, which is inspired by a scientific discovery made by neurosurgeon Ajmal Zemmar, aims to encourage people to reflect on life and the importance of all those moments that together make up each person's story.

Key Points: 
  • MADRID, Nov. 30, 2023 /PRNewswire/ -- Leading Galician liqueur brand Ruavieja has launched " The movie of your life ," its Christmas campaign designed by TBWA\Spain, the creative agency led by Juan García-Escudero.
  • Ruavieja has used this finding to create its Christmas campaign, which has a powerful message: a person's story is made up of shared moments that will be remembered at the very end.
  • Ruavieja then captured the moment when they watched the film, as well as their reactions, reminding us of the importance of spending time with the people we love.
  • The campaign takes the spirit of the iconic 2018 " We have to see more of each other " campaign and ends with the same slogan, reminding us to prioritise what really matters in life.

Ruavieja brings you another moving Christmas campaign

Retrieved on: 
星期四, 十一月 30, 2023
Frontiers Media, Advertising, Collection, University, University of Louisville, Ageing, Projection, Life, Film industry

MADRID, Nov. 30, 2023 /PRNewswire/ -- Leading Galician liqueur brand Ruavieja has launched "The movie of your life," its Christmas campaign designed by TBWA\Spain, the creative agency led by Juan García-Escudero. The project, which is inspired by a scientific discovery made by neurosurgeon Ajmal Zemmar, aims to encourage people to reflect on life and the importance of all those moments that together make up each person's story.

Key Points: 
  • MADRID, Nov. 30, 2023 /PRNewswire/ -- Leading Galician liqueur brand Ruavieja has launched " The movie of your life ," its Christmas campaign designed by TBWA\Spain, the creative agency led by Juan García-Escudero.
  • Ruavieja has used this finding to create its Christmas campaign, which has a powerful message: a person's story is made up of shared moments that will be remembered at the very end.
  • Ruavieja then captured the moment when they watched the film, as well as their reactions, reminding us of the importance of spending time with the people we love.
  • The campaign takes the spirit of the iconic 2018 " We have to see more of each other " campaign and ends with the same slogan, reminding us to prioritise what really matters in life.

Veterinarians, Veterinary Cardiologists and Animal Nutritionists Found Grain-Free Diets Had No Negative Impact on Heart Health of Dogs and Did Not Lead to DCM

Retrieved on: 
星期二, 十月 10, 2023
Multimedia, Heart, VTS, Doctor of Philosophy, Diet, Frontiers Media, University of Missouri College of Agriculture, Food and Natural Resources, University, Pea, ACAS, Veterinarian, CFS, Cardiology, Associate, Dog, Dilated cardiomyopathy, DCM, CVT, PAS, Nutrition, Research, Medical device, Animal feed

The research appeared in a peer-reviewed article in Frontiers in Animal Science .

Key Points: 
  • The research appeared in a peer-reviewed article in Frontiers in Animal Science .
  • "To identify any changes in cardiac function over time, our multi-disciplinary team collected and examined a wide cross-section of data."
  • Two diets were grain-free, contained pulse ingredients (peas and lentils) and potatoes, and included either low or high amounts of animal protein.
  • Two diets were grain-inclusive, contained no pulse ingredients or potatoes, and included either low or high amounts of animal protein.